rajasekharkakarla
☆    

India,
2019-09-20 06:35
(396 d 16:18 ago)

Posting: # 20628
Views: 1,253
 

 Reference replicated designs [Regulatives / Guidelines]

Dear All,

As per FDA guidelines "We recommend that if the predose value is greater than 5 percent of Cmax, you drop the subject from all BE study evaluations".

Is it applicable for fully replicated designs also, if i got greater than 5% Cmax in period 4 whether i need to exclude the subject from entire study or can we use available data for Swr calculations if subject completed two reference treatment periods.

Thanks&Regards,
Rajasekhar
Activity
 Admin contact
21,170 posts in 4,411 threads, 1,474 registered users;
online 9 (0 registered, 9 guests [including 2 identified bots]).
Forum time: Tuesday 22:54 CEST (Europe/Vienna)

In theory, there is no difference between theory and practice.
But, in practice, there is.    Jan L.A. van de Snepscheut

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5